Lymphoedema Evidence Library › Topics › Filariasis and tropical causes
Filariasis and tropical causes
Filariasis and tropical causes
24 sources
Evidence in one minute
- Lymphatic filariasis is the leading cause of lymphoedema worldwide (>120 million infected, ~40 million disfigured). Keast 2014 · Alavi unknown
- Drugs: diethylcarbamazine, albendazole, ivermectin clear microfilariae; doxycycline may reduce filarial lymphoedema (ISL) — not confirmed in a 2024 double-blind RCT, see update below (revised 2026-10-09); vigorous skin hygiene and antibiotics prevent elephantine change. Debulking in one or two stages for advanced (grade 3–4) disease. Executive Committee of the International Society of Lymphology 2023
- Diagnosis: filarial antigen card test (listed in the SA statement); programme diagnostics shift to rapid antigen mapping once mass drug administration starts. Davey 2018 · Molyneux 2009
- Psychological burden is severe and should be part of care. Person 2008
- Kaposi sarcoma (AIDS) causes lymphoedema in sub-Saharan Africa — a South African differential. Ebrahim 2009
- African surgical perspective (Tanzania co-authors): Silvestri 2024.
- Low-resource care models: World Alliance for Wound and Lymphoedema Care 2009.
Update 2026-10-08 — downloaded evidence
- Hygiene-based care: acute dermatolymphangioadenitis OR 0.32; self-care halves attacks. Stocks 2015 · Douglass 2016
- Podoconiosis: endemic in 18 African countries (up to 8% prevalence); prevented by footwear. Deribe 2018
- LF in Africa: 35 endemic countries; MDA coverage 62% (2018); morbidity services lagging. Deribe 2020
- Benzopyrone (coumarin) trials in filarial lymphoedema unreliable. Badger 2004
Gaps
Podoconiosis now covered (Deribe 2018). No data on filariasis prevalence in South Africa (not endemic; relevant to migrants).
Update 2026-10-09 — open-access batch 1 (2020–2026 trials and reviews)
- Doxycycline (revised 2026-10-09): a double-blind RCT of 200 patients in Kerala found no benefit of 6 weeks of doxycycline added to WHO hygiene-based care over 2 years (stage improved 10% v 21% with placebo) — moderate certainty of no benefit; the ISL 2023 statement that doxycycline may reduce filarial lymphoedema is not supported for stages 2–3. Parallel LEDoxy trials (Mali, Tanzania, Sri Lanka) to be appraised. Krishnasastry 2024
- Kaposi sarcoma (HIV): compression added to chemotherapy unproven (Kenyan pilot RCT, very low). Chang 2022
Update 2026-10-09 — open-access batch 2
- Doxycycline — all four LEDoxy trials (revised 2026-10-09): India (200), Mali (200), Tanzania (362, two doses) and Sri Lanka (200) — ~960 patients, double-blind, 24 months — found no benefit of a 6-week doxycycline course added to hygiene-based care on stage progression; placebo patients improved as much or more. Tanzania's claim of 'halted progression' comes from a post-hoc analysis. Rare serious harm (hepatic encephalopathy in undiagnosed Wilson's disease). Moderate certainty of no benefit — do not add doxycycline. Coulibaly 2024 · Ngenya 2024 · Yahathugoda 2024 · Krishnasastry 2024
- Hygiene matters most: an unclean limb doubled the hazard of an acute attack (Tanzania, HR ~2.4); rainy season doubled it again. Benefit of the hygiene package itself is uncontrolled (very low) but consistent across all sites.
Update 2026-10-09 — CME (S Afr) 2013 papers (Sabinet)
- Podoconiosis: asymmetric leg lymphoedema of barefoot farmers on volcanic soils; managed with washing, emollient, compression and shoes; preventable (Fuller 2013, narrative). Fuller 2013
- Indian village programme: washing, compression and ayurvedic care — large reductions reported in adherent patients only, 28% unaccounted for (Narahari 2013) — very low. Narahari 2013
Update 2026-10-09 — open-access batch 7
- Ayurvedic AYUSH-SL (Mitra 2025, placebo-controlled, India): both arms improved similarly (about 8% v 7% leg volume); the reported between-group p values mirror a baseline imbalance; the developer sponsored and analysed the trial — very low. Placebo plus mass drug administration and care improved QoL as much. Mitra 2025
How the evidence points
| High | Mod. | Low | V. low | None | |
|---|---|---|---|---|---|
| Positive | 0 | 0 | 2 | 0 | 0 |
| Null or negative | 0 | 4 | 0 | 3 | 0 |
Sources on this page with a comparison, by the result of their primary outcome and the GRADE certainty of their main finding (Mod. = Moderate, V. low = Very low, None = not graded). Context sources are not counted. How direction is decided.
All 24 sources
Loading 24 sources…